Familial adenomatous polyposis (FAP) is caused by mutations in the APC gene and 2 different, or biallelic mutations, in the MUTYH gene. However, not all patients with colorectal polyposis are found to ...

The hamartomatous polyposis syndromes are a heterogeneous group of disorders that share an autosomal-dominant pattern of inheritance and are characterized by hamartomatous polyps of the ...

Familial adenomatous polyposis is caused by a germ-line mutation in the adenomatous polyposis coli gene and is characterized by the development of hundreds of colorectal adenomas and, eventually, ...

Familial adenomatous polyposis is caused by abnormalities in the APC gene. The Food and Drug Administration (FDA) has granted Fast Track designation to REC-4881 for the treatment of familial ...

Juvenile polyposis syndrome (JPS) refers to a condition in which there are multiple benign polyps in the colon, or large intestine. Polyps are outgrowths occurring on the inside of a hollow organ. The ...

Patients with germline pathogenic variants (PVs) in APC develop tens (attenuated familial adenomatous polyposis [AFAP]) to innumerable (classic FAP) adenomatous polyps in their colon and are at ...

Please provide your email address to receive an email when new articles are posted on . Five-year survival for patients with MUTYH-associated polyposis colorectal cancer was 15% better than those with ...

Background A 22-year-old woman was referred to a genomic medicine clinic for evaluation of suspected Prader–Willi syndrome (PWS) after normal DNA methylation studies on chromosome 15 were obtained.

Role of independent data-monitoring committees in randomized clinical trials sponsored by the National Cancer Institute. BTP patients encompass a heterogeneous group that can be classified into two ...

Background A 64-year-old woman presented to the emergency room with a 3-month history of intermittent abdominal cramps, accompanied by nausea, vomiting, anorexia, and decreased bowel movements ...

Despite intranasal corticosteroid (INCs) being a treatment mainstay for chronic rhinosinusitis with nasal polyps, there are ongoing high rates of nonadherence, which can affect treatment efficacy, ...

in value terms by 2023-end and is projected to rise at a CAGR of 6.7% until 2033, according to a recently published report by Future Market Insights. By the end of the said forecast period, a ...